Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression
Open accessAbstract
The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly. In examining the effects of THC and CBD on microglial proliferation, we found that these compounds potently inhibit [3H]thymidine incorporation into a murine microglial cell line with no effect on cell cycle. Treatment with THC and CBD decreased [3H]thymidine uptake into microglia, with IC50 values that match inhibition of [3H]thymidine incorporation into DNA. CBD and, less potently, THC decreased uptake of [3H]adenosine to a similar extent as [3H]thymidine in both murine microglia and RAW264.7 macrophages. Binding studies confirm that CBD binds to the equilibrative nucleoside transporter 1 with a Ki < 250 nM. Because adenosine agonists have antiinflammatory effects, and because uptake of adenosine is a primary mechanism of terminating adenosine signaling, we tested the hypothesis that CBD is immunosuppressive because it enhances endogenous adenosine signaling. In vivo treatment with a low dose of CBD decreases TNFalpha production in lipopolysaccharide-treated mice; this effect is reversed with an A2A adenosine receptor antagonist and abolished in A2A receptor knockout mice. These studies demonstrate that CBD has the ability to enhance adenosine signaling through inhibition of uptake and provide a non-cannabinoid receptor mechanism by which CBD can decrease inflammation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Facilitation of adenosine signaling produces anxiolytic-like effects.
“facilitation of adenosine signaling produces anxiolytic-like effects (Carrier et al., 2006).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Carrier et al., 2006
CBD is an inhibitor of adenosine uptake.
“CBD is an inhibitor of adenosine uptake and facilitation of adenosine signaling produces anxiolytic-like effects (Carrier et al., 2006).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Carrier et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · see citing works
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819 · see citing works
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096 · see citing works
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 900 · see citing works
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669 · see citing works
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589 · see citing works
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570 · see citing works
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T. I., Zimmer, A. M., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 544 · see citing works
The cannabinoid system and immune modulation
Klein, T., Newton, C. A., Larsen, K. A., Lu, L. D., Perkins, I., Nong, L., & Friedman, H. P. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524 · see citing works
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 511 · see citing works
Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.
Howlett, A. C., Qualy, J. M., & Khachatrian, L. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10219-8 · Cited by 470 · see citing works
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A. D., Frossard, J., & Mach, F. (2005) · Nature · doi:10.1038/nature03389 · Cited by 469 · see citing works
Structure-activity relationships in cannabinoids.
Razdan, R. K. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06863-2 · Cited by 373 · see citing works
Nucleoside transporters: molecular biology and implications for therapeutic development
Baldwin, S. A., Mackey, J. R., Cass, C. E., & Young, J. D. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01459-8 · Cited by 345 · see citing works
Carrier, E. J., Kearn, C. S., Barkmeier, A. J., Breese, N. M., Yang, W., Nithipatikom, K., Pfister, S. L., Campbell, W. B., & Hillard, C. J. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.4.999 · Cited by 336 · see citing works
Self-citationAgonist Selective Regulation of G Proteins by Cannabinoid CB1and CB2Receptors
Glass, M., & Northup, J. K. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1362 · Cited by 289 · see citing works
Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., & Parolaro, D. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061002 · Cited by 272 · see citing works
Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Croxford, J. L., & Yamamura, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.023 · Cited by 256 · see citing works
Costa, B., Colleoni, M., Conti, S., Parolaro, D., Franke, C., Trovato, A. E., & Giagnoni, G. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0871-3 · Cited by 243 · see citing works
Kong, W., Engel, K., & Wang, J. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489162 · Cited by 240 · see citing works
Adenosine and Epilepsy: From Therapeutic Rationale to New Therapeutic Strategies
Boison, D. (2005) · The Neuroscientist · doi:10.1177/1073858404269112 · Cited by 217 · see citing works
Hyde, R. J., Cass, C. E., Young, J. D., & Baldwin, J. D. S. A. (2001) · Molecular Membrane Biology · doi:10.1080/09687680118799 · Cited by 214 · see citing works
High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock
Martin, C., Léone, M., Viviand, X., Ayem, M. L., & Guieu, R. (2000) · Critical Care Medicine · doi:10.1097/00003246-200009000-00014 · Cited by 194 · see citing works
Nucleoside transport and its significance for anticancer drug resistance
MACKEY, J., Baldwin, S. A., YOUNG, J., & Cass, C. E. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80047-2 · Cited by 149 · see citing works
Erdmann, A. A., Gao, Z., Jung, U., Foley, J., Borenstein, T., Jacobson, K. A., & Fowler, D. H. (2005) · Blood · doi:10.1182/blood-2004-04-1407 · Cited by 149 · see citing works
Sklar, M. D., Tereba, A., Chen, B. D. ‐., & Walker, W. S. G. (1985) · Journal of Cellular Physiology · doi:10.1002/jcp.1041250307 · Cited by 97 · see citing works
Kiss, A. J., FARAH, K., Kim, J., Garriock, R. J., Drysdale, T. A., & Hammond, J. R. (2000) · Biochemical Journal · doi:10.1042/bj3520363 · Cited by 92 · see citing works
Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC
Sòria, G., Castañé, A., Berrendero, F., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03682.x · Cited by 74 · see citing works
HPLC determination of adenosine in human synovial fluid
Sottofattori, E., Anzaldi, M., & Ottonello, L. C. (2001) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(00)00574-4 · Cited by 59 · see citing works
The effect of cannabidiol, alone and in combination with ethanol, on human performance
Belgrave, B. E., Bird, K. D., CHESHER, G. B., Jackson, D. M., Lubble, K. E., Starmer, G. A., & Teo, R. K. C. (1979) · Psychopharmacology · doi:10.1007/bf00496070 · Cited by 57 · see citing works
Selley, D. E., Cassidy, M. P., Martin, B. R., & Sim‐Selley, L. J. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.000604 · Cited by 40 · see citing works
Noji, T., Takayama, M., Mizutani, M., Okamura, Y., Takai, H., Karasawa, A., & Kusaka, H. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.200 · Cited by 33 · see citing works
A Na+-Dependent Nucleoside Transporter in Microglia
Hong, M., Schlichter, L. C., & Bendayan, R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35301-7 · Cited by 32 · see citing works
Dar, M. S., & Mustafa, S. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03599-0 · Cited by 29 · see citing works
Modulation of Adenosine Effects in Attenuation of Ischemia and Reperfusion Injury in Rat Heart
Hirai, K., & Ashraf, M. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0745 · Cited by 26 · see citing works
Smith, P. G., Thomas, H., Barlow, H. C., Griffin, R., Golding, B. T., Calvert, A. H., Newell, D. R., & Curtin, N. J. (2001) · PubMed · doi:10.25405/ncl.34601625 · Cited by 16 · see citing works
Chronic ethanol-induced heterologous desensitization is mediated by changes in adenosine transport.
Gordon, A. S., Nagy, L. E., Mochly‐Rosen, D., & Diamond, I. (1990) · PubMed · Cited by 15 · see citing works
INHIBITION BY THC OF THYMIDINE TRANSPORT: A PLASMA MEMBRANE EFFECT
Desoize, B., Léger, C., Jc, J., & Nahas, G. G. (1979) · Elsevier eBooks · doi:10.1016/b978-0-08-023759-6.50017-2 · Cited by 4 · see citing works
[delta-9-Tetrahydrocannabinol (THC) inhibition of the membrane transport system for thymidine].
Desoize, B., Léger, C.-L., & Nahas, G. (1978) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Pertwee, R. G. (2004) in Cannabinoids, ed. Di Marzo, V. (Kluwer Academic͞ Plenum Publishers, New York), pp. 32-83.
- Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R. & Feldmann, M. (2000) Proc. Natl. Acad. Sci. USA 97, 9561-9566.
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · see citing works
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,953 · see citing works
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535 · see citing works
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · see citing works
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946 · see citing works
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 851 · see citing works
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 839 · see citing works
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763 · see citing works
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 625 · see citing works
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622 · see citing works
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 582 · see citing works
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573 · see citing works
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas
Stella, N. (2010) · Glia · doi:10.1002/glia.20983 · Cited by 529 · see citing works
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · see citing works
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 513 · see citing works
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 482 · see citing works
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465 · see citing works
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446 · see citing works
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 402 · see citing works
Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0504-08.2008 · Cited by 392 · see citing works
Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads
Russo, E. B., & Marcu, J. P. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.03.004 · Cited by 379 · see citing works
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · see citing works
Fernández‐Ruíz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R. G., Mechoulam, R., & Martínez-Orgado, J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 356 · see citing works
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · see citing works
Adenosine signaling and function in glial cells
Boison, D., Chen, J., & Fredholm, B. B. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.131 · Cited by 306 · see citing works
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 300 · see citing works
Martín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298 · see citing works
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 297 · see citing works
Cannabinoids in the management of difficult to treat pain
Russo, E. B. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1928 · Cited by 296 · see citing works
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.016 · Cited by 285 · see citing works
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 282 · see citing works
Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279 · see citing works
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Devinsky, O., Nabbout, R., Miller, I., Laux, L., Żołnowska, M., Wright, S., & Roberts, C. (2018) · Epilepsia · doi:10.1111/epi.14628 · Cited by 273 · see citing works
El‐Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S. A., Radwan, M. M., Slade, D., Khan, I. A., ElSohly, M. A., & Ross, S. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.004 · Cited by 271 · see citing works
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
Oláh, A., Tóth, B. I., Borbíró, I., Sugawara, K., Szöllõsi, A. G., Czifra, G., Pál, B., Ambrus, L., Kloepper, J., Camera, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci64628 · Cited by 268 · see citing works
de Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 264 · see citing works
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 264 · see citing works
Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+Levels
Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4212-08.2009 · Cited by 258 · see citing works
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255 · see citing works
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 256 · see citing works
Cannabinoids: Therapeutic Use in Clinical Practice
Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., & Laezza, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063344 · Cited by 250 · see citing works
Turcotte, C., Chouinard, F., Lefebvre, J. S., & Flamand, N. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0115-021r · Cited by 249 · see citing works
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Jones, N. A., Glyn, S., Akiyama, S., Hill, T. D. M., Hill, A. J., Weston, S. E., Burnett, M. D. A., Yamasaki, Y., Stephens, G. J., Whalley, B. J., et al. (2012) · Seizure · doi:10.1016/j.seizure.2012.03.001 · Cited by 248 · see citing works
Booz, G. W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.007 · Cited by 246 · see citing works
Molecular Pharmacology of Phytocannabinoids
Turner, S. E., Williams, C. M., Iversen, L. L., & Whalley, B. J. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_3 · Cited by 246 · see citing works
Crestani, C. C., Alves, F. H. F., Gomes, F. V., Resstel, L. B. M., Corrêa, F. M. D. A., & Herman, J. P. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311020002 · Cited by 245 · see citing works
Cannabinoids in the Treatment of Epilepsy
Friedman, D. J., & Devinsky, O. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1407304 · Cited by 243 · see citing works
Adenosine kinase, epilepsy and stroke: mechanisms and therapies
Boison, D. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.008 · Cited by 243 · see citing works
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 239 · see citing works
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works
Russo, E. B., Guy, G. W., & Robson, P. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790150 · Cited by 228 · see citing works
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
Perucca, E. (2017) · Journal of Epilepsy Research · doi:10.14581/jer.17012 · Cited by 225 · see citing works
The adenosine kinase hypothesis of epileptogenesis
Boison, D. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.002 · Cited by 224 · see citing works
Endocannabinoid system and mood disorders: Priming a target for new therapies
Micale, V., Marzo, V. D., Šulcová, A., Wotjak, C. T., & Drago, F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.002 · Cited by 222 · see citing works
Equilibrative nucleoside transporters—A review
Boswell-Casteel, R. C., & Hays, F. A. (2016) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2016.1210805 · Cited by 215 · see citing works
The Pharmacological Case for Cannabigerol
Nachnani, R., Raup‐Konsavage, W. M., & Vrana, K. E. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000340 · Cited by 214 · see citing works
Cannabinoids: Occurrence and Medicinal Chemistry
Appendino, G., Chianese, G., & Taglialatela‐Scafati, O. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794940888 · Cited by 209 · see citing works
Martı́nez, V., Iriondo‐DeHond, A., Borrelli, F., Capasso, R., del Castillo, M. D., & Abalo, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093067 · Cited by 188 · see citing works
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., Mariano-Souza, D. P., Quinteiro-Filho, W. M., Akamine, A. T., de Almeida, V. I., Quevedo, J., Dal‐Pizzol, F., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.043 · Cited by 186 · see citing works
Adenosine, caffeine, and sleep–wake regulation: state of the science and perspectives
Reichert, C. F., Deboer, T., & Landolt, H. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13597 · Cited by 183 · see citing works
“Nevertheless, it is interesting to note that one of the most abundant components in the native cannabis plant, cannabidiol, inhibits the ENT1 (Carrier et al., 2006).”
BackgroundBaron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 182 · see citing works
McGrath, S., Bartner, L. R., Rao, S., Packer, R. A., & Gustafson, D. L. (2019) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.254.11.1301 · Cited by 181 · see citing works
Maione, S., Piscitelli, F., Gatta, L., Vita, D. D., PETROCELLIS, L. D., Palazzo, E., de Novellis, V., & Marzo, V. D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01063.x · Cited by 176 · see citing works
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Cannabidivarin is anticonvulsant in mouse and rat
Hill, A. G., Mercier, M., Hill, T., Glyn, S., Jones, N., Yamasaki, Y., Futamura, T., Duncan, M., Stott, C., Stephens, G. J., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02207.x · Cited by 173 · see citing works
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Franco, V., & Perucca, E. (2019) · Drugs · doi:10.1007/s40265-019-01171-4 · Cited by 171 · see citing works
Hurd, Y. L., Yoon, M. J., Manini, A. F., Hernandez, S. H., Olmedo, R., Östman, M., & Jutras‐Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 167 · see citing works
Rimmerman, N., Ben-Hail, D., Porat, Z., Juknat, A., Kozela, E., Daniels, M. P., Connelly, P. S., Leishman, E., Bradshaw, H. B., Shoshan‐Barmatz, V., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.471 · Cited by 164 · see citing works
Molecular and Cellular Mechanisms of Action of Cannabidiol
Naya, N. M., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. A. (2023) · Molecules · doi:10.3390/molecules28165980 · Cited by 158 · see citing works
Pazos, M. R., Cinquina, V., Gómez, A., Layunta, R., Santos, M., Fernández‐Ruíz, J., & Martínez-Orgado, J. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.034 · Cited by 151 · see citing works
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 150 · see citing works
THC and CBD: Similarities and differences between siblings
Stella, N. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.022 · Cited by 149 · see citing works
Liou, G. I., Auchampach, J. A., Hillard, C. J., Zhu, G., Yousufzai, B. K., Mian, S., Khan, S. H., & Khalifa, Y. M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2196 · Cited by 148 · see citing works
Self-citationKis, B., Ifrim, F. C., Buda, V. O., Avram, Ș., Pavel, I. Z., Antal, D., Păunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235905 · Cited by 148 · see citing works
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 148 · see citing works
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147 · see citing works
Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.045 · Cited by 146 · see citing works
Cannabidiol arrests onset of autoimmune diabetes in NOD mice
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.029 · Cited by 143 · see citing works
Adenosinergic signaling in epilepsy
Boison, D. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.046 · Cited by 142 · see citing works
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833b33c5 · Cited by 141 · see citing works
Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products
Anderson, G. D., & Chan, L. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0400-9 · Cited by 141 · see citing works
The emerging role of the endocannabinoid system in cardiovascular disease
Pacher, P., & Steffens, S. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0145-8 · Cited by 139 · see citing works
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 136 · see citing works
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135 · see citing works
Hayakawa, K., Mishima, K., Hazekawa, M., Sano, K., Irie, K., Orito, K., Egawa, T., Kitamura, Y., Uchida, N., Nishimura, R., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.090 · Cited by 134 · see citing works
Kaplan, B. L. F., Springs, A. E. B., & Kaminski, N. E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.022 · Cited by 132 · see citing works
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129 · see citing works
Durst, R. Y., Danenberg, H. D., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., & Lotan, C. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00098.2007 · Cited by 129 · see citing works
Oláh, A., Szekanecz, Z., & Bı́ró, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01487 · Cited by 123 · see citing works
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00589.x · Cited by 121 · see citing works
Li, H., Chang, S., Chang, T., You, Y., Wang, X. A., Wang, L., Yuan, X., Tan, M., Wang, P., Xu, P., et al. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116070 · Cited by 119 · see citing works
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels
Sales, A. J., Crestani, C. C., Guimarães, F. S., & Joca, S. R. L. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.002 · Cited by 118 · see citing works
Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity
Fouad, A. A., Albuali, W. H., Al-Mulhim, A. S., & Jresat, I. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.04.018 · Cited by 116 · see citing works
Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Gao, F., Coppola, G., Geschwind, D. H., & Vogel, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061462 · Cited by 116 · see citing works
Social Stress and Psychosis Risk: Common Neurochemical Substrates?
Mizrahi, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.274 · Cited by 115 · see citing works
Cannabidiol for neurodegenerative disorders: A comprehensive review
Bhunia, S., Kolishetti, N., Yndart, A., Vashist, A., & Nair, M. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989717 · Cited by 115 · see citing works
Patel, A. D., Mazurkiewicz‐Bełdzińska, M., Chin, R., Gil‐Nagel, A., Gunning, B. W., Halford, J. J., Mitchell, W. G., Perry, M. S., Thiele, E. A., Weinstock, A., et al. (2021) · Epilepsia · doi:10.1111/epi.17000 · Cited by 114 · see citing works
- Authors
- Carrier, E. J., Auchampach, J. A., & Hillard, C. J.
- Affiliations
- Medical College of Wisconsin (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-05-16
- Volume
- 103
- Issue
- 20
- Pages
- 7895-7900
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2067960394
- Cited by
- 497
- References
- 39
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 29 · 2023: 33 · 2022: 40 · 2021: 33 · 2020: 40 · 2019: 32 · 2018: 19 · 2017: 25 · 2016: 20 · 2015: 19 · 2014: 11 · 2013: 20 · 2012: 24
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL 077707, R01HL077707)
- National Institute on Drug Abuse (R01DA009155, DA 16967, DA09155, R01DA016967)
- National Institute of Neurological Disorders and Stroke (NS041314, R01NS041314)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Keywords
- cannabidiol, delta-9-tetrahydrocannabinol, equilibrative nucleoside transporter 1, adenosine uptake, adenosine signaling, adenosine A2A receptor, microglial proliferation, macrophages, TNF-α, lipopolysaccharide-induced inflammation, anti-inflammatory activity
- MeSH terms
- Rimonabant, Adenosine, Animals, Camphanes, Cannabidiol, Cell Line, DNA, Immunosuppression Therapy, Lipopolysaccharides, Male, Mice, Inbred C57BL, Piperidines, Psychotropic Drugs, Pyrazoles, Dronabinol, Thymidine, Tumor Necrosis Factor-alpha, Microglia, Nucleoside Transport Proteins, Equilibrative Nucleoside Transporter 1, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
